| Perpetual Credit Income Trust (PCI) ORDINARY UNITS FULLY PAID |
Financials |
$789 |
PCI Monthly Investment Report- June 2025
|
16 Jul 2025 10:41AM |
$1.185 |
$1.080 |
fallen by
8.86%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$77 |
Imugene Capital Raising Presentation
|
16 Jul 2025 10:40AM |
$0.425 |
$0.240 |
fallen by
43.53%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene Limited is undertaking a capital raising via placement and rights issue to fund its immuno-oncology pipeline.
- The company's pipeline includes multiple clinical and preclinical programs focused on innovative cancer immunotherapies.
- Key assets include HER-Vaxx, PD1-Vaxx, CF33 (VAXINIA & CHECKvacc), and other next-generation oncology candidates.
- Funds raised will support ongoing clinical trials, preclinical studies, and operational expenses.
- Imugene reports strong progress in several clinical trials, including HER-Vaxx (gastric cancer), PD1-Vaxx (non-small cell lung cancer), and the CF33 programs (solid tumours).
- The company has achieved significant regulatory and clinical milestones and anticipates several near-term catalysts.
- Management highlights a robust intellectual property portfolio and multiple opportunities for commercial partnerships.
- Imugene has outlined a clear pathway for value creation through the development and commercialization of its products.
- The presentation details the structure, terms, and expected proceeds from the capital raising activities.
- Imugene remains committed to advancing its mission to develop novel treatments that improve patient outcomes in oncology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$610 |
Final Distribution for 30 June 2025
|
16 Jul 2025 10:39AM |
$3.140 |
$2.740 |
fallen by
12.74%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$77 |
Proposed issue of securities - IMU
|
16 Jul 2025 10:39AM |
$0.425 |
$0.240 |
fallen by
43.53%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$77 |
Proposed issue of securities - IMU
|
16 Jul 2025 10:36AM |
$0.425 |
$0.240 |
fallen by
43.53%
|
|
| Imugene Limited (IMU) ORDINARY FULLY PAID |
Health Care |
$77 |
Imugene Completes $22.5M Placement and c.$15M SPP
|
16 Jul 2025 10:36AM |
$0.425 |
$0.240 |
fallen by
43.53%
|
|
IMU - Price-sensitive ASX Announcement
Full Release
Key Points
- Imugene completed a $22.5M placement and approximately $15M via Share Purchase Plan (SPP).
- Proceeds will be used to advance clinical trials for Imugene’s immunotherapy candidates.
- The capital raising received strong support from both institutional and retail investors.
- Funds will support ongoing and future clinical programs, operational expansion, and general corporate activities.
- The announcement reiterates Imugene’s commitment to developing innovative immunotherapies for cancer.
- Details are provided on the allocation of shares, pricing, and the closing of the SPP.
- Recent board and operational updates are included, highlighting strategic priorities.
- The company expresses gratitude to shareholders for their continued support and participation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hawsons Iron Ltd (HIO) ORDINARY FULLY PAID |
Materials |
$21 |
Proposed issue of securities - HIO
|
16 Jul 2025 10:31AM |
$0.021 |
$0.017 |
fallen by
19.05%
|
|
| Plato Income Maximiser Limited (PL8) ORDINARY FULLY PAID |
Financials |
$1,086 |
Net Tangible Asset Backing
|
16 Jul 2025 10:26AM |
$1.400 |
$1.450 |
risen by
3.57%
|
|
| Ophir High Conviction Fund (OPH) ORDINARY UNITS FULLY PAID |
Financials |
$610 |
Update - Dividend/Distribution - OPH
|
16 Jul 2025 10:22AM |
$3.120 |
$2.740 |
fallen by
12.18%
|
|
| Beacon Minerals Limited (BCN) ORDINARY FULLY PAID |
Materials |
$450 |
Near Surface Laterite Mineralisation Identified at Iguana
|
16 Jul 2025 10:18AM |
$1.100 |
$4.040 |
risen by
267.27%
|
|
BCN - Price-sensitive ASX Announcement
Full Release
Key Points
- Beacon Minerals Limited identified near surface laterite mineralisation at the Iguana prospect.
- The mineralisation contains elevated nickel, cobalt, and scandium values.
- Aircore drilling confirmed broad zones of mineralisation, open in several directions.
- Further drilling and systematic sampling are planned to better define mineralisation.
- The project is part of the Jaurdi Gold Project in Western Australia.
- Beacon is expanding exploration efforts into battery metals.
- Existing infrastructure and project experience at Jaurdi will be leveraged for new exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hawsons Iron Ltd (HIO) ORDINARY FULLY PAID |
Materials |
$21 |
Update - Proposed issue of securities - HIO
|
16 Jul 2025 10:17AM |
$0.021 |
$0.017 |
fallen by
19.05%
|
|
| Ark Mines Limited (AHK) ORDINARY FULLY PAID |
Materials |
$31 |
Investor Presentation
|
16 Jul 2025 10:15AM |
$0.150 |
$0.435 |
risen by
190%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$218 |
Investor Briefing Presentation
|
16 Jul 2025 10:15AM |
$0.029 |
$0.275 |
risen by
848.28%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$218 |
Investor Briefing Invitation
|
16 Jul 2025 10:13AM |
$0.029 |
$0.275 |
risen by
848.28%
|
|
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$218 |
Reinstatement to Quotation
|
16 Jul 2025 10:11AM |
$0.029 |
$0.275 |
risen by
848.28%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos Diagnostics Holdings Limited (ASX: LDX) will be reinstated to official quotation on the ASX.
- Reinstatement follows the company meeting ASX Listing Rule requirements.
- Details provided on capital raisings and changes to the board structure.
- Background given on the previous suspension of LDX shares.
- Steps outlined that LDX took to address issues leading to suspension.
- Reinstatement process and implications for shareholders are explained.
- Company has improved its financial position and governance structure.
- ASX confirms all necessary documentation and compliance are satisfied.
- Trading in LDX securities will recommence on 13 June 2024.
- Shareholders are advised of the process and next steps following reinstatement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lumos Diagnostics Holdings Limited (LDX) ORDINARY FULLY PAID |
Health Care |
$218 |
Lumos Signs Pivotal US FebriDx Agreement
|
16 Jul 2025 10:11AM |
$0.029 |
$0.275 |
risen by
848.28%
|
|
LDX - Price-sensitive ASX Announcement
Full Release
Key Points
- Lumos Diagnostics Holdings Limited has signed a pivotal US clinical trial agreement for FebriDx.
- The agreement is aimed at obtaining FDA clearance for FebriDx in the United States.
- FebriDx is a point-of-care diagnostic test that distinguishes between bacterial and viral infections.
- The agreement marks a significant step in Lumos Diagnostics’ US market strategy.
- The clinical trial is essential for the commercial launch of FebriDx in the US healthcare sector.
- The document discusses the clinical, regulatory, and commercial significance of the agreement.
- Details include projected timelines and the scope of the pivotal clinical study for FDA approval.
- The agreement may positively impact Lumos Diagnostics’ competitive position and financial prospects.
- Risks and contingencies related to FDA approval and market adoption are addressed.
- The agreement is a major advancement towards expanding Lumos Diagnostics' presence in the US diagnostics market.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zeus Resources Limited (ZEU) ORDINARY FULLY PAID |
Energy |
$9 |
Zeus Appoints US Business Development & Strategy Advisor
|
16 Jul 2025 10:08AM |
$0.017 |
$0.012 |
fallen by
29.41%
|
|
| Clean TeQ Water Limited (CNQ) ORDINARY FULLY PAID |
Industrials |
$39 |
Initial Director's Interest Notice - D Pfeffer
|
16 Jul 2025 10:05AM |
$0.210 |
$0.445 |
risen by
111.90%
|
|
| Monash IVF Group Limited (MVF) ORDINARY FULLY PAID |
Health Care |
$253 |
Appointment of Interim Chief Financial Officer
|
16 Jul 2025 10:04AM |
$0.730 |
$0.650 |
fallen by
10.96%
|
|
| Anson Resources Limited (ASN) ORDINARY FULLY PAID |
Materials |
$87 |
Anson Successfully Polishes Green River Lithium Chloride
|
16 Jul 2025 10:03AM |
$0.092 |
$0.054 |
fallen by
41.30%
|
|
ASN - Price-sensitive ASX Announcement
Full Release
Key Points
- Anson Resources successfully produced high-purity lithium chloride from Green River brine.
- The lithium chloride concentrate meets battery-grade requirements after proprietary polishing.
- The project is located in Utah, USA, targeting the US battery and EV markets.
- Production is an important step toward commercial battery-grade lithium output.
- The high-purity lithium chloride will be further processed into lithium carbonate and hydroxide.
- Ongoing project activities include permitting, site works, and preparing for commercial operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clean Seas Seafood Limited (CSS) ORDINARY FULLY PAID |
Consumer Staple |
- |
Court Approves Scheme of Arrangement
|
16 Jul 2025 10:02AM |
$0.135 |
$0.135 |
fallen by
0%
|
|
| Clean TeQ Water Limited (CNQ) ORDINARY FULLY PAID |
Industrials |
$39 |
Appointment of New Director
|
16 Jul 2025 10:01AM |
$0.210 |
$0.445 |
risen by
111.90%
|
|
| Lord Resources Limited (LRD) ORDINARY FULLY PAID |
Materials |
$3 |
Notification regarding unquoted securities - LRD
|
16 Jul 2025 10:01AM |
$0.023 |
$0.018 |
fallen by
21.74%
|
|
| Caspin Resources Limited (CPN) ORDINARY FULLY PAID |
Materials |
$40 |
Completion of Tranche 2 Placement and Cleansing Statement
|
16 Jul 2025 10:00AM |
$0.051 |
$0.160 |
risen by
213.73%
|
|
| Caspin Resources Limited (CPN) ORDINARY FULLY PAID |
Materials |
$40 |
Notification regarding unquoted securities - CPN
|
16 Jul 2025 10:00AM |
$0.051 |
$0.160 |
risen by
213.73%
|
|